Approved for Active immunization for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older. RSV vaccine (adjuvanted, recombinant) contains a stabilized prefusion F glycoprotein antigen that elicits neutralizing antibodies against RSV, preventing viral entry into respiratory epithelial cells. Side effects, costs, interactions, manufacturer, and generic…
Loading full data from Know Your Drugs Institute…